We Claim,

1. An immunogenic composition comprising:
   a) one or more Influenza virus at a dose of 6 to 7 Log EID_{50} per 0.5 ml; and
   b) a stabilizer composition comprising
      i. 1 to 10% (w/v) sucrose;
      ii. 0.1% to 2% (w/v) of histidine;
      iii. 0.01% to 1% (w/v) alanine;
      iv. 0.1% to 2% (w/v) tricine;
      v. 0.1 to 5% (w/v) arginine; and
      vi. 0.1 to 5% (w/v) gelatin.

2. The immunogenic composition as claimed in claim 1, wherein the influenza virus comprise of pandemic or seasonal Influenza virus, a live attenuated influenza vaccine (LAIV) virus, an inactivated influenza virus, a chimeric influenza virus, or a recombinant influenza virus.

3. The immunogenic composition as claimed in claim 1, wherein composition is monovalent in terms of Influenza virus derived from Influenza type A or type B or type C or its subtypes.

4. The immunogenic composition as claimed in claim 1, wherein composition is multivalent in terms of Influenza virus derived from Influenza type A or type B or type C or its subtypes.

5. The immunogenic composition as claimed in claim 1, wherein Influenza virus are reassortant LAIV virus comprising cold adapted, temperature sensitive and/or attenuated phenotype gene segments of master donor viruses (MDVs) and haemagglutinin (HA) and/or neuraminidase (NA) gene segments of the wild type pandemic or seasonal influenza type A or B or C virus strains in a ratio of 1:7, 2:6, 3:5, 4:4, 5:3, 6:2 or 7:1.

6. The immunogenic composition as claimed in claim 5, wherein master donor virus (MDVs) is selected from the group comprising of A/Leningrad/ 134/ 17/57 (H2N2) Influenza A strain, B/USSR/60/69 Influenza B strain.

7. The immunogenic composition as claimed in claim 5, wherein the reassortant LAIV virus comprise of the haemagglutinin (HA) gene and/or neuraminidase (NA) gene from the influenza A virus or HI to H18 and N1 to Ni l and its subtypes H1N1, H2N2, H3N2, H5N1, H5N3, H9N2, H7N1, H7N3, H7N7, H6N1, H7N9, or H10N8.

8. The immunogenic composition as claimed in claim 5, wherein the reassortant LAIV virus comprise of the haemagglutinin (HA) gene and/or neuraminidase (NA) gene from the influenza A virus strain pdmHlNl strain - A/Califomia/07/2009 (referred to as A/Cal)-like strain or A/Cal, A/Michigan/45/2015-like strain, A/South-Africa/3626/2013 like strain, or H3N2-A/Hong Kong/4801/2014-like strain.

9. The immunogenic composition as claimed in claim 5, wherein the reassortant LAIV virus comprise of the haemagglutinin (HA) gene and/or neuraminidase (NA) gene from the influenza B virus strain Victoria lineage-B/Brisbane/60/2008-like strain or Yamagata lineage- B/Phuket/3073/2013-like strain.

10. The immunogenic composition as claimed in claim 1, wherein the composition additionally comprises an adjuvant selected from the group of aluminum hydroxide, aluminum phosphate, aluminum hydroxyphosphate, and potassium aluminum sulfate or a mixture thereof.

11. The immunogenic composition as claimed in claim 1, wherein the single dose composition is free of preservative and the multi-dose composition comprises of one or

more preservative selected from the group of 2-phenoxyethanol, Benzethonium chloride (Phemerol), Phenol, Thiomersal, Formaldehyde, methylparaben, propylparaben, benzyl alcohol or a combination thereof.

12. The immunogenic composition as claimed in claim 1, wherein the composition comprises of a buffer selected from sodium chloride, carbonate, citrate, lactate, gluconate, tartrate, phosphate buffer saline, HEPES, Citrate-phosphate or TRIS.

13. The immunogenic composition as claimed in claim 1, wherein the composition comprises of a pharmaceutically acceptable transporter, excipient, binder, carrier, isotonic agent, emulsifier or humectant.

14. The immunogenic composition as claimed in claim 13, wherein the composition comprises pharmaceutically acceptable excipient selected from the group of sugars, polyols, salts including NaCl, KC1, KH_2PO_4, $Na_2HPO_4.2H_2O$, $CaCl_2$, or $MgCl_2$., amino acids or pH modifiers.

15. The immunogenic composition as claimed in claim 1, wherein the final pH of the immunogenic composition comprises of pH 6.5 to 8.

16. The immunogenic composition as claimed in claim 1, wherein the Influenza type B virus is present at a dose of 6 to 7 Log EID_{50} per 0.5 ml; more preferably NLT 6.5 Log EID_{50} per 0.5 ml.

17. The immunogenic composition as claimed in claim 1, wherein the Influenza type A virus is present at a dose of 6 to 7 Log EID_{50} per 0.5 ml; more preferably NLT 7 Log EID_{50} per 0.5 ml.

18. A method of preparing an immunogenic composition as claimed in claim1, said method comprises following steps:

a) Infecting MDCK Cell culture host with Influenza virus at a MOI between 1:100 to 1:10000
b) Harvesting of Supernatant comprising Influenza virus post incubation period of 40 to 70 hrs in MEM containing trypsin in the range of 5 to 25U/ml;
c) Filtering the viral harvest by direct flow filtration (DFF) through at least one clarification filter having a pore size of between about 6 micrometers to about 0.45 micrometers;
d) Treating the CVP with a non-specific endonuclease at temperature ranging in between 30-34°C for 2 to 6 hours and subsequently at temperature of 2 to 8°C for 5 to 15 hours;
e) Concentrating the endonuclease treated CVP by tangential flow filtration (TFF) using a membrane with a molecular weight cut off (MWCO) of l00KDa - 500KDa;
f) Stabilizing the TFF concentrate with a stabilizer composition comprising one or more carbohydrate, one or more amino-acid and gelatin to form a stabilized viral harvest; and
g) Sterilizing the stabilized TFF concentrate by DFF through at least one sterilization grade filter having a pore size of between about 0.8 micrometers to about 0.2 micrometers to form a sterilized CMVP; wherein the overall recovery of purified viruses is more than or equal to 40%.

19. The method as claimed in claim 18, wherein the Influenza virus is propagated in Madin Darby canine kidney (MDCK) cells (ATCC CCL-34).

20. The method of manufacturing the immunogenic composition as claimed in 18, wherein the step (d) comprises of treating the viral harvest with non-specific endonuclease more particularly Benzonase having concentration in the range of 0.5 units / ml to 5 units / ml in presence of divalent cation selected from the group consisting of Ca^{2+}, Mg^{2+}, Mn^{2+}, and Cu^{2+} in amount between 0.1 mM and 100 mM.

21. The method of manufacturing the immunogenic composition as claimed in 18, wherein the step (d) comprises of treating the viral harvest with non-specific endonuclease more particularly Benzonase having concentration in the range of 0.5 units / ml to 5 units / ml in presence of a divalent cation Mg^{2+} salt at concentration of 1 to 3 mM.

22. The method of manufacturing the immunogenic composition as claimed in 18, wherein the step (e) comprises of concentrating the viral harvest by tangential flow filtration (TFF) resulting in at least 4X concentration of viral harvest.

23. The method of manufacturing the immunogenic composition as claimed in 18, wherein the step (f) comprises of stabilizing the viral harvest with a stabilizer composition comprising sucrose at a concentration of 1 to 10% (w/v), histidine at a concentration of 0.1% to 2% (w/v), alanine at a concentration of 0.01% to 1% (w/v), tricine at a concentration of 0.1% to 2% (w/v), arginine at a concentration of 0.1 to 5% (w/v) and gelatin at a concentration of 0.1 to 5% (w/v).

24. The method of manufacturing the immunogenic composition as claimed in 18, wherein the step (f) comprises of stabilizing the viral harvest with a stabilizer composition comprising sucrose at a concentration of 3 to 6% (w/v), histidine at a concentration of 0.1% to 1% (w/v), alanine at a concentration of 0.05% to 0.5% (w/v), tricine at a concentration of 0.1% to 0.5% (w/v), arginine at a concentration of 0.1 to 3% (w/v) and gelatin at a concentration of 0.1 to 3% (w/v).

25. The method of manufacturing the immunogenic composition as claimed in 18, wherein the step (f) comprises of stabilizing the viral harvest with a stabilizer composition comprising sucrose 4% (w/v), histidine 0.21% (w/v), alanine 0.1% (w/v), tricine 0.3% (w/v), arginine 2.1% (w/v) and gelatin 0.85% (w/v).

26. The method of manufacturing the immunogenic composition as claimed in 18, wherein the step (f) comprises of stabilizing the viral harvest with a stabilizer composition

comprising sucrose 4% (w/v), histidine 0.21% (w/v), alanine 0.1% (w/v), tricine 0.3% (w/v), arginine 2.1% (w/v) and gelatin 1.0% (w/v).

27. The method of manufacturing the immunogenic composition as claimed in 18, wherein the step (f) comprises of stabilizing the viral harvest with a stabilizer composition comprising sucrose 4% (w/v), histidine 0.21% (w/v), alanine 0.1% (w/v), tricine 0.3% (w/v), arginine 1.6% (w/v) and gelatin 1.0% (w/v).

28. The immunogenic composition as claimed in claim 1, wherein the immunogenic composition is formulated for in a human subject using one of intranasal, intramuscular, intravenous, subcutaneous, transcutaneous or intradermal route; and wherein the immunogenic composition is formulated as single dose vials or multidose vials or multidose kit or as pre-filled syringes or nasal sprays for reducing the onset of or preventing a health condition comprising Influenza A virus infection or its subtypes, Influenza B virus infection or its subtypes or Influenza C virus infection or its subtypes.

29. The immunogenic composition as claimed in claim 1, wherein the composition comprises:
    a) One or more live attenuated Influenza vaccine (LAIV) virus at a dose of 6 to 7 Log EID_{50} per 0.5 ml;
    b) Sucrose 3 to 6% (w/v);
    c) Histidine 0.1% to 1% (w/v);
    d) Alanine 0.05% to 0.5% (w/v);
    e) Tricine 0.1% to 0.5% (w/v);
    f) Arginine 0.1 to 3% (w/v); and
    g) Gelatin 0.1 to 3% (w/v).

30. The immunogenic composition as claimed in claim 1, wherein the composition comprises:

a) One or more live attenuated Influenza vaccine (LAIV) virus at a dose of 6 to 7 Log EID_{50} per 0.5 ml;
b) Sucrose 4% (w/v);
c) Histidine 0.21% (w/v);
d) Alanine 0.1% (w/v);
e) Tricine 0.3% (w/v);
f) Arginine 2.1% (w/v); and
g) Gelatin 0.85% (w/v).

31. The immunogenic composition as claimed in claim 1, wherein the composition comprises:
    a) One or more live attenuated Influenza vaccine (LAIV) virus NLT at a dose of 6 to 7 Log EID_{50} per 0.5 ml;
    b) Sucrose 4% (w/v);
    c) Histidine 0.21% (w/v);
    d) Alanine 0.1% (w/v);
    e) Tricine 0.3% (w/v);
    f) Arginine 2.1% (w/v); and
    g) Gelatin 1% (w/v).

32. The immunogenic composition as claimed in claim 1, wherein the composition comprises:
    a) One or more live attenuated Influenza vaccine (LAIV) virus at a dose of 6 to 7 Log EID_{50} per 0.5 ml;
    b) Sucrose 4% (w/v);
    c) Histidine 0.21% (w/v);
    d) Alanine 0.1% (w/v);
    e) Tricine 0.3% (w/v);
    f) Arginine 1.6% (w/v); and
    g) Gelatin 1% (w/v).